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ABSTRACT
Objective: To compare the clinical efficacy and safety of rectal dihydroartemisinin (DATM
- Cotecxin) and intravenous quinine in the treatment of severe malaria in children and adults.
Setting: Moi Teaching and Referral Hospital, Eldoret, Kenya between July and November
1998.
Patients: A total of sixty seven patients aged two to sixty years with severe malaria were
studied.
Design: This was an open randomised comparative clinical trial.
Outcome measures: These were parasite clearance time, fever clearance time, efficacy and
the side effect profile of the two drugs.
Results: The two groups were comparable on admission on the clinical and laboratory
parameters. The parasite clearance time was shorter in the rectal DATM group than quinine
group. There was no statistical difference on the fever clearance time and cure rates in the
two groups. The adverse reaction profile was better with rectal DATM than with quinine,
tinnitus observed more in the quinine group.
Conclusion: Rectal DATM is faster in parasite clearance than quinine and is a safe and
convenient alternative to quinine in the treatment of severe malaria.
INTRODUCTION
There are an estimated 300 - 500 million clinical cases
in sub-Saharan Africa with between 1.5 - 3 million deaths
of which one million are due to cerebral malaria(1-3).
Commonly used drugs in the treatment of malaria in
Kenya include the 4-aminoquinolones (chloroquine,
amodiaquine); pyrimethamine - sulphonamide
combinations and quinine. Newer additions include
mefloquine, halofantrine and derivatives of artemisinin(4).
Over the last few years, multi-drug resistant strains
have developed rapidly against established antimalarial
drugs. Falciparum malaria resistance to most of these
commonly used drugs has been demonstrated widely
except artemisinin derivatives(4,7-9). This multi-drug
resistance is a matter of great concern, especially in areas
where high risk of malaria infection and morbidity are
coupled with weak economies(9).
Artemisinin is a sesquiterpene lactone peroxide
derivative of qinghaosu identified by Chinese scientists in
1985(5). These compounds are thought to be effective
against multiple drug resistant P. falciparum malaria
(uncomplicated and complicated)(5,6). Furthermore
artemisinin and its derivatives act on the early ring stage
parasites and may therefore prevent sequestration in the
brain unlike quinine and other antimalarials which act on
the mature stages of the parasites when sequestration of
the parasitised erythrocytes in the brain is believed to have
occurred(7).
Artemisinin is marketed in various preparations but
artemisinin suppository was developed and approved for
use in the treatment of falciparum malaria in China in
1985. Clinical trials so far carried out indicate that
artemisinin derivatives including rectal dihydroartemisinin
(DATM) have faster parasite clearance rates than
intravenous quinine(5-7,10-12).
Rectal DATM therefore could be a more convenient,
cheap and effective alternative to the currently used
antimalarials. The increasing rate of multidrug resistance
of P. falciparum, high costs of drugs and, related equipment
necessary for their administration (intravenous lines; fluids
for quinine) necessitate the need for cheap, convenient and
effective antimalarials.
Rectal DATM is a new drug with a new mode of
administration which would meet the above
requirements(6,13). This study was therefore conducted
with the aim of establishing the efficacy and safety of
DATM in comparison to quinine in the treatment of severe
P. falciparum malaria.
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Supportive management: Intravenous fluids (other than
10% dextrose for quinine), electrolytes and 50% dextrose were
administered according to each patients requirements as assessed
by the study physicians and according to laboratory reports.
Antipyretics were administered as necessary when the temperature
was ≥38.5°C. Complications such as convulsions, acidosis,
heart failure, respiratory failure or acute renal failure were dealt
with using conventional modes of therapy used at the hospital.
Clinical methods: Baseline observations and investigations
were done on admission and the relevant data entered in the
prescribed data sheets.
All study patients were hospitalised for a minimum of seven
days and discharged after review by a study physician on day six.
Temperature, pulse rate and respiratory rate were observed
6 hourly and blood pressure twice daily until discharge.
Side effects were looked for and recorded in a prescribed
form every morning and evening.
Laboratory tests: Parasitology: Potential study patients
were screened to confirm the adequacy of P. falciparum malaria
parasites for inclusion into the study. Peripheral thin and thick
blood smears were prepared from patients’ finger prick. These
were allowed to dry and thin films were fixed in absolute alcohol
(methanol) after which both films were stained in 10% Giemsa
stain diluted in buffered water pH 7.1 - 7.2. The smears were
allowed to dry after which they were examined under oil
immersion objective. Thin smears were used to identify malaria
species while the thick films were used for counting the parasites.
Malaria parasites present were counted per 200 White Blood
Cells (WBC) and these counts were converted to number of
parasites per microlitre blood using the formula below:
Total WBC Count x No. of Parasites per 200 WBC = No. of Parasites/
200 µl Blood
WBC total count of 7200/µl blood was used for the calculation
of the number of parasites per µl of blood in this study in all cases
as this is the average WBC count for MTRH population.
Patients who had asexual form counts of ≥300 /µl/blood of
P. falciparum were recruited into the study pending investigations
of other inclusion criteria. This was recorded as O hour blood
smear after which subsequent five thick smear samples were
taken at an interval of 8 hours up to 48 hours followed by two
thick smears taken daily at 12 hour intervals up to Day 4 and
thereafter once daily in the morning of Day 5 and Day 6. P.
falciparum gametocytes (PFG) present were also counted and
reported per 200 WBCs in all the smears done. The smears were
regarded negative when no gametocytes or any of the asexual
forms were found in 200 fields in three consecutive smears.
Candidate patients’ blood was taken in anticoagulated and plain
vacutainers for haematological and biochemical analyses
respectively.
Haematological investigations: Anticoagulated blood from
each patient was taken on Day 0 and Day 6, and processed for
estimation of haematological indices. Each blood sample was
drawn into Coulter Counter (CC) and appropriate dilutions done
automatically after which different indices were estimated using
inbuilt techniques in the CC machine. The estimated
haematological indices were read off the CC print-out. The
indices estimated were White Blood Cells (WBC [103/µl]), Red
Blood Cells (RBC [103/µl]), Haemoglobin (Hb [g/dl]) and
Haematocrit (HCT [%]). Peripheral thin blood films were made
using anticoagulated blood for each study patient on Day 0 and
Day 6. These were stained using Giemsa stain and examined for
polymorph differential counts under oil immersion objective.
MATERIALS AND METHODS
Patients: Consecutive patients aged 2 - 60 years from Uasin
Gishu District, Kenya admitted to Moi Teaching and Referral
Hospital (MTRH) with malaria positive blood slides and fulfilling
the WHO criteria for severe malaria(14) were recruited into the
study.
Inclusion criteria (as severe malaria) were: (i) patients with
cerebral malaria with Glasgow Coma Scale of 8 or less; (ii)
patients with severe anaemia with haemoglobin levels of less
than 5 gm/dl.; (iii) patients with hyperparasitaemia (parasite
counts of more than 100,000/ul); (iv) patients with hyperpyrexia
(temperature on admission of ≥41°C); (v) patients with profuse
vomiting (gastrointestinal symptoms); (vi) patients with evidence
of haemolysis or black water fever; (vii) patients in shock (algid
malaria) and; (viii) patients with a combination of any of the
above on admission.
Exclusion criteria were: (i) patients who had been on any
antimalarial in the last 72 hours before admission and; (ii)
pregnancy.
Patients with severe diarrhoea were excluded in both groups
due to the rectal route of administration of Cotecxin in the study
group. Informed and written consent was obtained from all
patients or their guardians before inclusion into the study.
Blinding: This was an open randomised comparative clinical
trial.
Randomisation: A computer was used to generate numbers
for randomisation into the Cotecxin and Quinine treatment
groups. Those code listed ‘A’ got Cotecxin and ‘B’ got Quinine.
The list was from 1 to 200 with ‘A’ or ‘B’ randomly assigned to
each of these numbers. The patients were then assigned to either
Cotecxin or Quinine on consecutive basis using this list starting
from serial 1.
Antimalarial regimen: The duration of therapy in both
groups was seven  days and patients in either group were changed
to oral medication for the last four  days if they were able to take
oral medication.
DATM: Dihydroartemisinin suppositories (Cotecxin
suppository-Beijing COTEC New Technologies Corp. P.R.
China) were administered rectally in the dose outlined below
according to age. In children above eight years and adults, tablets
were administered from 72 hours to day six. For those less than
eight years, DATM paediatric powder at the same dosage as for
suppositories was used.
Regimen of DATM suppository/tablet/powder
Age Daily doses (mg) Total
(years) (mb)
D0 D1 D2 D3 D4 D5 D6
≥16 160 80 80 80 80 80 80 640
11-15 120 60 60 60 60 60 60 480
7-10 80 40 40 40 40 40 40 320
3-6 60 30 30 30 30 30 30 240
2 40 20 20 20 20 20 20 160
Quinine: Quinine dihydrochloride (Dawa Pharmaceuticals,
Kenya) was given intravenously in a dose of 20mg/kg body
weight loading dose for the first 8 hours then 10 mg/kg given 8
hourly in 10% dextrose drip until they were able to take orally.
In children under eight years and those who for any reason could
not take oral quinine from 72 hours intra-muscular quinine was
administered upto six days.
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The thin smears were also used to report on the morphology,
shape and size of the Red Blood Cells (RBCs).  Any abnormalities
detected on platelets were also reported.
Biochemistry tests:  Sera were separated from the clotted
blood samples after which these were used for the estimations of
various biochemical parameters. The standard biochemical
methods for the serum transaminases (ALT and AST) creatinine
and bilirubin were used. The biochemical tests were done on Day
O and Day 6. The results obtained were recorded in the patients’
individual files.
Urinalysis: Freshly voided urine samples were collected
from each study patient on Day O and Day 6. Urinalysis tests
were done on the samples using the urine dipstick model(17).
The parameters determined were Specific Gravity (SG), pH,
protein, glucose, bilirubin and urobilinogen, ketones, blood and
WBC.
Evaluation of efficacy and side effects: Parasite clearance
times in each case was calculated and mean values between two
groups were compared. Fever clearance time (FCT) was calculated
for each case and the mean fever clearance time between the two
groups were compared. Fever was considered to have subsided
if the temperature remained below 37.5°C for at least 24 hours
and thereafter. Side effects of the two groups were analysed and
a comparison made.
Data analysis: Data was entered into the computer and the
Microsoft excel statistical programme was used for data analysis.
RESULTS
The patients in the two groups were comparable in
clinical and laboratory parameters as shown in Table 1.
There were no statistical significant differences between
the two groups. The overall male to female ratio was 1:1.4
(quinine=1:1.6; cotexcin=1: 1.1). The distribution of the
patients clinical signs and symptoms were comparable on
admission between the two groups (Tables 2 and 3). The
end points except for parasite clearance were comparable
between the two groups (Table 4).
Table 1
Patient clinical and laboratory characteristics on admission
Characteristic Quinine (n=37) Cotecxin (n=30) t-test-p=0.05
Mean Range Cl Mean Range Cl 2-tail
Age (yrs) 14.9±3.9 2.5-42 11-18.8 13.1±4.8 2.5-50 8.4-17.9 0.58
Duration of
illness (days) 3.2±0.7 1-7 2.5-3.9 4.1±1.0 1-14 3.1-5.1 0.15
Malaria episodes
in last six months 0.5±0.3 0-4 0.2-0.9 0.9±0.4 0-4 0.5-1.3 0.2
Length of stay in
Eldoret (yrs) 11.3±2.5 2.5-30 8.8-13.8 9.0±3.1 3-38 5.9-12 0.35
Duration of fever (days) 3.2±0.7 1-7 2.5-3.8 3.7±1.0 1-14 2.7-4.7 0.43
Temperature (°C) 38.4±0.3 36.2-41.0 38.1-38.7 38.3±0.3 36.5-40 38.0-38.6 0.96
Pulse rate/min 109±7 80-140 102-116 111±7 80-140 104-118 0.87
Respiratory
rate/min 29±2 20-44 27-31 28±3 18-40 25-31 0.49
Weight (kg) 21.8±5.2 9-78 16.6-27 16.5±1.9 10-38 14.6-18.4 0.23
Parasite count /Ê1/ 49472±29130 300-304950 20342-78602 29448±11877 300-130400 17571-41325 0.16
Gametocyte count /Ê1/ 222±10 13-678 121-323 196±107 71-640 89-303 0.91
Red blood cell
count (x109/) 3.9±0.3 1.63-5.36 3.6-4.1 3.97±0.37 1.9-6.7 3.6-4.3 0.78
Haematocrit (%) 33.2±2.4 16.4-48.8 30.8-35.6 32.7±2.8 18.8-49.4 29.9-35.5 0.79
White blood cell
count/cumm 7984±1656 2200-22600 6328-9640 8328±1271 2300-19600 7057-9599 0.75
Haemoglobin (g/dl) 10.5±1.0 3.9-17.4 9.5-11.5 10.2±1.1 5.1-16.8 9.1-11.3 0.76
Alanine aminotransferase
iÊ/I 14.4±4.4 3.5-62.5 9.7-18.5 11.2±2.2 2.5-28.8 9.0-13.4 0.27
Aspartate
aminotransferase iu/l 23.2±10.6 5.2-185.1 12.6-33.8 19.1±5.8 3.5-224.9 13.3-24.9 0.52
Serum bilirubin
(Êmol/l) 13.1±4.3 2-56.5 8.8-17.6 19.5±10.0 2-131.9 9.5-29.5 0.26
Serum creatinine
(mmol/l) 95.8±13.3 28.5-229.8 82.5-1009.1 79.5±13.4 12.7-175.8 66.1-92.9 0.12
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Table 2
Symptoms and signs on admission
Symptom/finding Quinine Cotecxin t-test
(n=37)% (n=30)% (p=0.05)
Sweating 38 53 0.97
Confusion 26 23 0.46
Headache 84 83 0.78
Chills 73 86 0.2
Vomiting 59 52 0. 58
Diarrhoea 24 21 0.79
Abdominal pain 59 41 0.22
Cough 42 45 0. 85
Jaundice 3 7 0. 72
Bleeding 3 0 0. 98
Palpable spleen 12 24 0.54
Palpable liver 3 3 0.87
Urinalysis on admission was comparable in both groups for protein, pH,
specific gravity, ketones, sugar and cytology. There was no difference in
prior use of antimalarials between the two groups. Antimalarial use prior
to admission was the same in the two groups.
Table 3
Distribution of the patients among the various severe forms of
malaria
Severe malaria type Quinine (n=37) Cotecxin (n=30)
Cerebral malaria 4 6
Severe anaemia 3 4
Hyperparasitaemia 8 8
Hyperpyrexia 1 1
Severe vomiting 8 6
Algid malaria (shock) 0 0
Black water fever 0 0
Combination of two or
more of above 13 5
*There is no statistical difference between the groups. P≥0.05
Side effects: There was a higher number of cases with
tinnitus in the quinine group (n=10) than the Cotecxin
group (n=1). The other side effects were pruritus and
anorexia which were observed with equal frequency in the
two groups. There were no side effects in 24 and 27 cases
for quinine and cotecxin groups respectively.
Efficacy: RI resistance could not be established as
we did not follow our patients beyond seven days,
however RII and RIII resistance were not observed in
either groups.
Table 4
Patients characteristics at end of the study
Characteristic Quinine (n=37) Cotecxin (n=30) t-test
(p=0.05)
Mean Range Cl Mean Range Cl p
Parasite clearance time (hrs) 49±8.9 16-90 40.1-57.9 38.4±6.5 8-72 31.9-49.9 0.04
Gametocyte clearance time (hrs) 9±2.1 1-16 6.9-11.1 7.3±2.9 6-16 4.4-10.2 0.78
Fever clearance time (hrs) 22±4.9 0*-60 17.1-26.9 27.9±8.3 0*-80 19.6-36.2 0.25
Haematocrit on discharge 45±18.5 23.7-49 26.5-63.5 32.1±3 22.8-42.7 29.1-35.1 0.2 1
Total wbc on
discharge/cumm 9885±1382 3800-204000 8503-11267 9270±1351 4500-20000 7919-10621 0. 56
Haemoglobin on
discharge (g/dl) 11.2±0.7 6.2-16.5 9.5-12.9 10.1±1.0 5.4-14.9 9.1-11.1 0.13
Alanine aminotransferase on
discharge (iu/l) 9.9±2.8 3.5-31.4 7.1-12.7 26.8±1.9 5.2-254.8 7.8-45.8 0.11
Aspartate aminotransferase on
discharge (iu/l) 9.9±1.8 2.6-19.2 8.1-11.7 17.2±7.6 4.4-107.4 9.6-24.8 0.09
Total bilirubin on
discharge (Êmol/l) 5.0±1.5 1-28.8 3.5-6.5 8.3±4.4 2-58.5 3.9-12.7 0.19
Creatinine on discharge
(mmol/l) 64.4±6.4 18.0-123.8 58-70.8 66.9±7.3 33-108.1 59.6-74.2 0.64
The parasite clearance time was statistically different between the two groups. Urinalysis on discharge was comparable in both groups as was the case
on admission.
*0 here indicates that some patients in both groups presented without fever on admission.





Fever and parasite clearance times: Figure 1a and 1b
show the parasite and fever clearance times for quinine
and cotecxin. The mean parasite clearance time for quinine
and cotecxin was 48 hrs and 38.5 hrs respectively, the
difference is statistically significant (p=0.04). The mean
fever clearance time for quinine and cotecxin was 22hrs
and 27.5 hrs respectively, the difference is not statistically
significant (p=0.25). These are also shown in Table 3.
DISCUSSION
Severe malaria is a leading cause of morbidity and
mortality in Kenya and other sub-Saharan African
countries(1-3). This has been compounded by the fast
spreading multi-drug resistance and the declining
economies in these countries. These factors have
neccesitated the search for cheap, effective, safe and easy
to administer drugs especially for rural settings where the
logistics for parenteral modes of therapy may not be
practicable. Current antimalarials for severe malaria have
severe side effects and are associated with logistics and
supplies needed for their administration.
The use of rectal formulations of the artemisinin
derivatives has been seen to be the most appropriate
therapy to overcome most of these difficulties and a
number of studies are under way on this front. Some
studies have already been conducted with very good
results using other derivatives of artemisinin (artesunate,
artemether, among others) but DATM has not been tried
outside China and this study could be the first using the
DATM derivative suppository(10-13). These artemisinin
derivatives have been found to be safe and convenient as
they require only a once a day dosage(12).  They have been
found to be more efficacious than quinine when given in
the rectal formulation as well as the parenteral route(11,12).
Our results show that rectal DATM has a faster parasite
clearance than intravenous quinine but the fever clearance
time was the same for the two drugs. These findings agree
with similar studies so far conducted elsewhere using
rectal formulations of artemisinin(12).
There were no deaths in this study for both groups and
the cure rate was the same in the two treatment groups. No
RII or RIII resistance was demonstrated as there was
complete parasite clearance in all patients by 84 hours in
all groups and no parasites were detected on discharge on
the seventh day. RI resistance could not be established as
we did not follow up our patients beyond seven days for
logistic reasons. These results are similar to those reported
in the literature in which rectal or parenteral artemisinin
derivatives have been compared with quinine formulations
in severe malaria(10-13). The results for the fever clearance
time have been variable within the studies unlike for
parasite clearance where universally the artemisinin
derivatives have shorter times than quinine. The fever
clearance time in some studies have been found to be
shorter in the artemisinin than for quinine but other studies
have found no statistical differences in the fever clearance
time as was found in our study(12-16).
There were relatively less side effects with rectal
DATM than quinine but this was not statistically significant
except for tinnitus which was frequently observed among
the quinine patients than among the DATM group. Renal
function, liver function and haematological parameters all
improved in both the quinine and cotecxin group. This
agrees with findings in other studies(10-13). The cost
effectiveness analysis of DATM and quinine has not been
worked out in this study but would be worth looking at and
determine whether DATM is cheaper than quinine when
the overall cost of treatment of the patient rather than the
market cost of them individually is considered. The unit
cost of rectal DATM is not known in Kenya as it has not
been in the market but the tablet formulation has been in
the market for several years.
Cultural resentment would be expected to be one of
hindrances to be encountered with use of rectal formulations
of artemisinin, however, this was not found to be the case
in this study as it was readily accepted. This will however,
need a larger sample size for a reliable conclusion to be
arrived at.
In conclusion, from the results of this study, rectal
DATM is easier to administer and faster in parasite
clearance than quinine and has a better adverse reactions
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profile. It would therefore be a safe, effective; easy to
administer and convenient alternative to quinine in the
treatment of severe malaria in both children and adults
especially in peripheral health units with limited staff and
supplies.
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